NKTR Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -486.44% compared to Nektar Therapeutics's net margin of 40.12%. Nektar Therapeutics's return on equity of -201.73% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

Nektar Therapeutics has a consensus price target of $96.80, signalling upside risk potential of 201.64%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.29 which suggests that it could grow by 55.35%. Given that Nektar Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Catalyst Pharmaceuticals.

Nektar Therapeutics has a beta of 0.552, which suggesting that the stock is 44.806% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.922%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Nektar Therapeutics's net income of -$50.9M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 14.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.92x versus 5.19x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -486.44% compared to Nektar Therapeutics's net margin of -108.46%. Nektar Therapeutics's return on equity of -201.73% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Nektar Therapeutics has a consensus price target of $96.80, signalling upside risk potential of 201.64%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 141.77%. Given that Nektar Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Nektar Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Nektar Therapeutics has a beta of 0.552, which suggesting that the stock is 44.806% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Nektar Therapeutics's net income of -$50.9M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.92x versus 5.88x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -486.44% compared to Nektar Therapeutics's net margin of 26.7%. Nektar Therapeutics's return on equity of -201.73% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Nektar Therapeutics has a consensus price target of $96.80, signalling upside risk potential of 201.64%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 39.24%. Given that Nektar Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Regeneron Pharmaceuticals.

Nektar Therapeutics has a beta of 0.552, which suggesting that the stock is 44.806% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Nektar Therapeutics's net income of -$50.9M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.92x versus 4.23x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of -486.44% compared to Nektar Therapeutics's net margin of -147.92%. Nektar Therapeutics's return on equity of -201.73% beat Xencor's return on equity of -32.34%.

Nektar Therapeutics has a consensus price target of $96.80, signalling upside risk potential of 201.64%. On the other hand Xencor has an analysts' consensus of $28.20 which suggests that it could grow by 230.21%. Given that Xencor has higher upside potential than Nektar Therapeutics, analysts believe Xencor is more attractive than Nektar Therapeutics.

Nektar Therapeutics has a beta of 0.552, which suggesting that the stock is 44.806% less volatile than S&P 500. In comparison Xencor has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.145%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $10.5M, which are smaller than Xencor quarterly revenues of $32.7M. Nektar Therapeutics's net income of -$50.9M is lower than Xencor's net income of -$48.4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 3.92x versus 4.57x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.